Gujarat Themis Biosyn's revenue increased 48.6% YoY
  • 15 Nov 2026
  • Gujarat Themis Biosyn Ltd reported a 22.3% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 48.6%.
  • Its expenses for the quarter were up by 121.6% QoQ and 165.3% YoY.
  • The net profit decreased 225.0% QoQ and decreased 252.8% YoY.
  • The earnings per share (EPS) of Gujarat Themis Biosyn Ltd declined at 1.19 during Q2 FY 2026-27.

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Gujarat Themis Biosyn Ltd is a company involved in the biotechnology industry, focusing primarily on the production of various pharmaceutical products. The company's offerings are centered around the manufacturing and development of active pharmaceutical ingredients (APIs) and other related chemical compounds essential for drug formulation. As a player in the biosynthesis sector, the company is engaged in leveraging biological processes for the production of these compounds. While specific recent developments were not provided, companies in this sector often engage in research and development to enhance their product lines and maintain competitiveness within the industry.

During Q2FY27, Gujarat Themis Biosyn Ltd reported a total income of ₹53.72 crores. This represents a significant increase of 22.3% quarter-over-quarter (QoQ) from ₹43.92 crores in Q1FY27, and a 48.6% year-over-year (YoY) growth from ₹36.15 crores in Q2FY26. Such growth in revenue over these periods reflects an upward trend in the company’s ability to generate income from its operations. The increase in total income could be indicative of enhanced sales volume, pricing adjustments, or an expanded product portfolio, although specific factors are not detailed in the data provided.

The financial data for Q2FY27 shows that Gujarat Themis Biosyn Ltd experienced a decline in profitability. The company recorded a loss before tax of ₹11.17 crores, contrasting with a profit before tax of ₹15.17 crores in Q1FY27 and ₹12.12 crores in Q2FY26. This shift marks a negative change of 173.6% QoQ and 192.2% YoY. Furthermore, the profit after tax was negative, standing at a loss of ₹13.84 crores for Q2FY27, compared to profits of ₹11.07 crores in Q1FY27 and ₹9.06 crores in Q2FY26, reflecting changes of -225.0% QoQ and -252.8% YoY. The earnings per share (EPS) also decreased to -₹1.19, down from ₹1.02 in the previous quarter and ₹0.83 in the same quarter last year, indicating a decline of 216.7% QoQ and 243.4% YoY.

The company’s total expenses for Q2FY27 were reported at ₹63.73 crores, which is a sharp increase of 121.6% from ₹28.76 crores in Q1FY27 and 165.3% from ₹24.02 crores in Q2FY26. This substantial rise in expenses over the periods analyzed may have contributed to the observed decline in profitability. The tax expenses for Q2FY27 were ₹2.67 crores, a decrease of 34.9% from the previous quarter's ₹4.10 crores, and a 12.7% decrease from ₹3.06 crores in Q2FY26. This reduction in tax expenses, despite the increase in total expenses, aligns with the overall decrease in profitability. The financial data does not provide additional operating metrics such as specific cost components, but the significant increase in total expenses warrants attention to cost management and operational efficiency.

Gujarat Themis Biosyn Ltd announced its Q2 FY 2026-27 results on 15 November, 2026.

Gujarat Themis Biosyn Ltd quarterly results refer to the company’s financial performance over a three-month period, including key metrics like revenue, net profit, earnings per share (EPS), and margin performance.

Key highlights of Gujarat Themis Biosyn Ltd Q2 FY 2026-27 results include:

  • Revenue: ₹53.72 crore
  • Net Profit: ₹-13.84 crore
  • EBITDA: ₹1.72 crore
  • Year-over-Year Growth: 48.6%
  • Quarter-over-Quarter Growth: 22.3%

Gujarat Themis Biosyn Ltd reported a net loss of ₹-13.84 crore in Q2 FY 2026-27, reflecting a -252.8% year-over-year growth.

Gujarat Themis Biosyn Ltd posted a revenue of ₹53.72 crore in Q2 FY 2026-27.